Antibody-Dependent Cell Cytotoxicity

"Antibody-Dependent Cell Cytotoxicity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The phenomenon of antibody-mediated target cell destruction by non-sensitized effector cells. The identity of the target cell varies, but it must possess surface IMMUNOGLOBULIN G whose Fc portion is intact. The effector cell is a "killer" cell possessing Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.

Descriptor ID	D000920
MeSH Number(s)	G12.287.070
Concept/Terms	Antibody-Dependent Cell Cytotoxicity Antibody-Dependent Cell Cytotoxicity Antibody Dependent Cell Cytotoxicity Cell Cytoxicity, Antibody-Dependent Antibody-Dependent Cell Cytoxicities Antibody-Dependent Cell Cytoxicity Cell Cytoxicities, Antibody-Dependent Cell Cytoxicity, Antibody Dependent Cytoxicities, Antibody-Dependent Cell Cytoxicity, Antibody-Dependent Cell ADCC Cytotoxicity, Antibody-Dependent Cell Antibody-Dependent Cell Cytotoxicities Cell Cytotoxicities, Antibody-Dependent Cell Cytotoxicity, Antibody-Dependent Cytotoxicities, Antibody-Dependent Cell Cytotoxicity, Antibody Dependent Cell

Below are MeSH descriptors whose meaning is more general than "Antibody-Dependent Cell Cytotoxicity".

Biological Sciences [G]
Immune System Phenomena [G12]
Cytotoxicity, Immunologic [G12.287]
Antibody-Dependent Cell Cytotoxicity [G12.287.070]

Below are MeSH descriptors whose meaning is related to "Antibody-Dependent Cell Cytotoxicity".

Below are MeSH descriptors whose meaning is more specific than "Antibody-Dependent Cell Cytotoxicity".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antibody-Dependent Cell Cytotoxicity" by people in this website by year, and whether "Antibody-Dependent Cell Cytotoxicity" was a major or minor topic of these publications.

Bar chart showing 35 publications over 21 distinct years, with a maximum of 3 publications in 2008 and 2010 and 2014 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	1	2
1998	0	1	1
1999	1	0	1
2000	1	1	2
2001	0	1	1
2002	1	0	1
2003	0	1	1
2005	0	1	1
2006	0	1	1
2008	3	0	3
2009	1	1	2
2010	0	3	3
2011	0	2	2
2012	1	1	2
2014	0	3	3
2015	0	2	2
2016	0	1	1
2017	0	1	1
2018	1	2	3
2019	1	0	1
2021	1	0	1

Below are the most recent publications written about "Antibody-Dependent Cell Cytotoxicity" by people in Profiles.

Li C, Chong G, Zong G, Knorr DA, Bournazos S, Aytenfisu AH, Henry GK, Ravetch JV, MacKerell AD, Wang LX. Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fc? Receptor Affinity and ADCC Activity. J Am Chem Soc. 2021 05 26; 143(20):7828-7838.

View in: PubMed
Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Cancer Immunol Res. 2019 10; 7(10):1633-1646.

View in: PubMed
Giddens JP, Lomino JV, DiLillo DJ, Ravetch JV, Wang LX. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. Proc Natl Acad Sci U S A. 2018 11 20; 115(47):12023-12027.

View in: PubMed
Tomalka AG, Resto-Garay I, Campbell KS, Popkin DL. In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol. 2018; 9:2552.

View in: PubMed
Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV, Waldmann TA. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci U S A. 2018 11 13; 115(46):E10915-E10924.

View in: PubMed
Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A. 2017 03 28; 114(13):3485-3490.

View in: PubMed
Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J. An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget. 2016 Dec 27; 7(52):86359-86373.

View in: PubMed
DiLillo DJ, Ravetch JV. Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell. 2015 May 21; 161(5):1035-1045.

View in: PubMed
Hart JD, Lutz CT, Jennings CD, May JR, Nelson K, Jacobs S, Hoopes CW. Falsely incompatible B-cell flow cytometry crossmatch after pronase treatment: a case report. Transplant Proc. 2015 Apr; 47(3):831-3.

View in: PubMed
Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, Scheinberg DA. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein. Clin Cancer Res. 2014 Aug 01; 20(15):4036-46.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement